Anthera Pharmaceuticals, Inc. announced the appointment of James Pennington, M.D. as interim Chief Medical Officer following the Company's acceptance of Colin Hislop's resignation effective April 1st, 2016. Dr. Pennington assumes the position of interim Chief Medical Officer with over 40 years of successful clinical development and commercialization including 14 drug approvals and 10 registration ex-US approvals including both small and large molecule therapeutics. Dr. Pennington joined Anthera in 2007 as Executive Vice President and Chief Medical Officer and transitioned to Senior Clinical Fellow in 2010.

Prior to joining Anthera in 2007, Dr. Pennington served as Executive Vice President and Chief Medical Officer of CoTherix where he oversaw the approval of Ventavis®. He previously served as Chief Medical Officer of InterMune as well as in a variety of positions at early stage biotech companies and large global pharmaceutical companies including Alpha Therapeutic Corporation, Shaman Pharmaceuticals and Bayer Corporation. Dr. Pennington spent 12 years as a member of the Harvard Medical School faculty.